Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)
Jessica Mandrioli(University of Modena and Reggio Emilia), Angelo Poletti(University of Milan), Roberto D’Amico(University of Modena and Reggio Emilia), Elisabetta Zucchi(University of Modena and Reggio Emilia), Mario Sabatelli(Barrow Neurological Institute), Vincenzo Silani(University of Milan), Vito D’Agostino(University of Trento), Isabella Laura Simone(University of Turin), Alessandro Provenzani(University of Trento), V. Crippa(University of Milan), Maria Rosaria Monsurrò(University of Cagliari), Valentina Bonetto(Mario Negri Institute for Pharmacological Research), Annalisa Gessani(Azienda Unita' Sanitaria Locale Di Modena), Mauro Ceroni(University of Pavia), Nilo Riva(HUN-REN Institute of Experimental Medicine), Adriano Chiò(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Serena Carra(University of Modena and Reggio Emilia), Gianni Sorarú(University of Padua), Cristina Cereda(University of Milan)
Cited by 68
Related Papers
Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
|Science|2015|980
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
|Neuron|2018|724
Characterization of human disease phenotypes associated with mutations in <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADAR</i>, and <i>IFIH1</i>
|American Journal of Medical Genetics Part A|2015|617